A new daily pill, orforglipron, demonstrated significant weight loss in a large-scale clinical trial lasting 72 weeks.
Twenty percent of participants achieved a remarkable 20% or more weight reduction, showcasing its potential effectiveness.
Unlike injectable options, this pill offers increased convenience and accessibility, potentially transforming obesity treatment.
Although not yet approved, the promising results suggest it could revolutionize weight management, expanding treatment options for many.
